Background Severe trauma represents a major global public health burden and the
management of post-traumatic bleeding continues to challenge healthcare systems around …

Objectives We review the evidence for tranexamic acid (TXA) for the treatment and
prevention of bleeding caused by surgery, trauma and bleeding disorders. We highlight …

METHODS We performed a single-center, prospective, cluster randomized, prehospital
through in-hospital whole blood pilot trial for injured air medical patients. We compared …

BACKGROUND Hemorrhage is the leading cause of preventable death after injury. Others
have shown that delays in massive transfusion cooler arrival increase mortality, while …

Hemorrhagic shock in pediatric trauma patients remains a challenging yet preventable
cause of death. There is little high-quality evidence available to guide specific aspects of …

Introduction Over the last decade, tranexamic acid (TXA) has been incorporated into
treatment algorithms for a multitude of emergent conditions and the evidence surrounding its …

BACKGROUND Venous thromboembolism (VTE) remains a frequent postinjury complication
with well established but nonmodifiable risk factors. We hypothesized that fibrinolysis …

BACKGROUND In the Study of Tranexamic Acid During Air and Ground Prehospital
Transport (STAAMP) Trial, prehospital tranexamic acid (TXA) was associated with lower …

Background Tranexamic acid (TXA) has been hypothesized to mitigate coagulopathy in
patients after traumatic injury. Despite previous prehospital clinical trials demonstrating a …

BACKGROUND Growing evidence supports improved survival with prehospital blood
products. Recent trials show a benefit of prehospital tranexamic acid (TXA) administration in …